To evaluate the safety of the use of CW002 in healthy human volunteers by monitoring changes in ECG, heart rate (HR), mean arterial pressure, plasma histamine levels, clinical laboratory values, and noting the occurrence of adverse events.
To estimate the ED95 (dose required to produce 95% suppression of neuromuscular activity
18 Years to 49 Years (Adult)
April 20, 2011
February 4, 2014
Weill Cornell Medical College New York, New York, United States
† Study has passed its completion date and status has not been verified in more than two years.